These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 35026215)

  • 21. Lipopolysaccharide supports maintaining the stemness of CD133(+) hepatoma cells through activation of the NF-κB/HIF-1α pathway.
    Lai FB; Liu WT; Jing YY; Yu GF; Han ZP; Yang X; Zeng JX; Zhang HJ; Shi RY; Li XY; Pan XR; Li R; Zhao QD; Wu MC; Zhang P; Liu JF; Wei LX
    Cancer Lett; 2016 Aug; 378(2):131-41. PubMed ID: 27208741
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Research progression of CD133 as a marker of cancer stem cells.
    Zhang H; Li SY
    Chin J Cancer; 2010 Mar; 29(3):243-7. PubMed ID: 20193104
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression profile of intestinal stem cell and cancer stem cell markers in gastric cancers with submucosal invasion.
    Kim HS; Song HJ; Kim HU; Jeong IH; Koh HM; Shin JH; Jang BG
    Pathol Res Pract; 2021 Feb; 218():153336. PubMed ID: 33450435
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer.
    Joseph C; Arshad M; Kurozomi S; Althobiti M; Miligy IM; Al-Izzi S; Toss MS; Goh FQ; Johnston SJ; Martin SG; Ellis IO; Mongan NP; Green AR; Rakha EA
    Breast Cancer Res Treat; 2019 Apr; 174(2):387-399. PubMed ID: 30554343
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expressions of putative cancer stem cell markers ABCB1, ABCG2, and CD133 are correlated with the degree of differentiation of gastric cancer.
    Jiang Y; He Y; Li H; Li HN; Zhang L; Hu W; Sun YM; Chen FL; Jin XM
    Gastric Cancer; 2012 Oct; 15(4):440-50. PubMed ID: 22395309
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD133 and CD44 cell surface markers do not identify cancer stem cells in primary human gastric tumors.
    Rocco A; Liguori E; Pirozzi G; Tirino V; Compare D; Franco R; Tatangelo F; Palaia R; D'Armiento FP; Pollastrone G; Affuso A; Bottazzi EC; Masone S; Persico G; Nardone G
    J Cell Physiol; 2012 Jun; 227(6):2686-93. PubMed ID: 21898409
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ABCG2 is required for self-renewal and chemoresistance of CD133-positive human colorectal cancer cells.
    Ma L; Liu T; Jin Y; Wei J; Yang Y; Zhang H
    Tumour Biol; 2016 Sep; 37(9):12889-12896. PubMed ID: 27449042
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CD133 expression may be useful as a prognostic indicator in colorectal cancer, a tool for optimizing therapy and supportive evidence for the cancer stem cell hypothesis: a meta-analysis.
    Zhao Y; Peng J; Zhang E; Jiang N; Li J; Zhang Q; Zhang X; Niu Y
    Oncotarget; 2016 Mar; 7(9):10023-36. PubMed ID: 26840260
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of CD44 and CD133 as cancer stem cell markers for colorectal cancer.
    Wang C; Xie J; Guo J; Manning HC; Gore JC; Guo N
    Oncol Rep; 2012 Oct; 28(4):1301-8. PubMed ID: 22895640
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD133 expression and MYCN amplification induce chemoresistance and reduce average survival time in pediatric neuroblastoma.
    Zhong ZY; Shi BJ; Zhou H; Wang WB
    J Int Med Res; 2018 Mar; 46(3):1209-1220. PubMed ID: 29322842
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acquisition of tumorigenic potential and therapeutic resistance in CD133+ subpopulation of prostate cancer cells exhibiting stem-cell like characteristics.
    Kanwal R; Shukla S; Walker E; Gupta S
    Cancer Lett; 2018 Aug; 430():25-33. PubMed ID: 29775627
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro characterization of CD133
    Nair RM; Balla MM; Khan I; Kalathur RKR; Kondaiah P; Vemuganti GK
    BMC Cancer; 2017 Nov; 17(1):779. PubMed ID: 29162051
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New emerging roles of CD133 in cancer stem cell: Signaling pathway and miRNA regulation.
    Aghajani M; Mansoori B; Mohammadi A; Asadzadeh Z; Baradaran B
    J Cell Physiol; 2019 Dec; 234(12):21642-21661. PubMed ID: 31102292
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival.
    Silva IA; Bai S; McLean K; Yang K; Griffith K; Thomas D; Ginestier C; Johnston C; Kueck A; Reynolds RK; Wicha MS; Buckanovich RJ
    Cancer Res; 2011 Jun; 71(11):3991-4001. PubMed ID: 21498635
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemoresistance to 5-FU inhibited by 635 nm LED irradiation in CD133+ KB cell line.
    Kim D; Park M; Jang H; Hyun H; Lim W
    Lasers Med Sci; 2018 Jan; 33(1):57-66. PubMed ID: 28956217
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells.
    Bidlingmaier S; Zhu X; Liu B
    J Mol Med (Berl); 2008 Sep; 86(9):1025-32. PubMed ID: 18535813
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sox2, a stemness gene, regulates tumor-initiating and drug-resistant properties in CD133-positive glioblastoma stem cells.
    Song WS; Yang YP; Huang CS; Lu KH; Liu WH; Wu WW; Lee YY; Lo WL; Lee SD; Chen YW; Huang PI; Chen MT
    J Chin Med Assoc; 2016 Oct; 79(10):538-45. PubMed ID: 27530866
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.
    Ruscito I; Cacsire Castillo-Tong D; Vergote I; Ignat I; Stanske M; Vanderstichele A; Ganapathi RN; Glajzer J; Kulbe H; Trillsch F; Mustea A; Kreuzinger C; Benedetti Panici P; Gourley C; Gabra H; Kessler M; Sehouli J; Darb-Esfahani S; Braicu EI
    Eur J Cancer; 2017 Jul; 79():214-225. PubMed ID: 28525846
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro identification and characterization of CD133(pos) cancer stem-like cells in anaplastic thyroid carcinoma cell lines.
    Zito G; Richiusa P; Bommarito A; Carissimi E; Russo L; Coppola A; Zerilli M; Rodolico V; Criscimanna A; Amato M; Pizzolanti G; Galluzzo A; Giordano C
    PLoS One; 2008; 3(10):e3544. PubMed ID: 18958156
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression patterns of Thymosin β4 and cancer stem cell marker CD133 in ovarian cancers.
    Ji YI; Lee BY; Kang YJ; Jo JO; Lee SH; Kim HY; Kim YO; Lee C; Koh SB; Kim A; Lee JY; Jung MH; Ock MS; Cha HJ
    Pathol Oncol Res; 2013 Apr; 19(2):237-45. PubMed ID: 23055022
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.